Linaclotide

Therapeutic

Treatment of irritable bowel syndrome (IBS) with constipation and chronic idiopathic constipation.

Structural features

SMILES

[H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O

Sequence

C(1)C(2)EYC(3)C(1)NPAC(2)TGC(3)Y

Molar mass

1526.73 g/mol

Constitutional members:

14

Natural amino acids

14

D-Amino acids

0

N-terminus

H

C-terminus

COOH

Cyclic

yes

Members/cycle

multicyclic

Bond to form cycle

3 side chain-to-side chain (disulfide)

Lipidation

no

Glycosylation

no

Route of administration

ORAL

Terminal half-life

Can't be calculated because not sistemically absorbed

Protein binding

-

Absorption and Bioavailability

When taken orally, linaclotide is not absorbed into the systemic

References